Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Rhea-AI Summary

Sol-Gel Technologies (Nasdaq: SLGL) announced its participation in the Jefferies London Healthcare Conference on November 16-17, 2021. Dr. Alon Seri-Levy, CEO, will present live on November 16 from 8:00 to 8:35 AM GMT. The presentation will discuss Sol-Gel’s focus on developing treatments for skin diseases, including the FDA-approved TWYNEO for acne and EPSOLAY, which is pending FDA action. The company is also advancing early-stage candidates targeting other dermatologic conditions.

For more details, visit www.sol-gel.com.

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Jefferies London Healthcare Conference, taking place in-person on November 16^th and 17^th, 2021.

Jefferies London Healthcare Conference Presentation Information:
Format	Live presentation and 1-on-1 in person meetings
Speaker:	Dr. Alon Seri-Levy, Chief Executive Officer
Date:	Tuesday, November 16th 2021
Time:	8:00-8:35 AM GMT
To Listen	To listen to the presentation, click here. A replay will be archived for 30 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section).

About Sol-Gel Technologies

Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021.  Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma

The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.
For additional information, please visit www.sol-gel.com.

Contact:

Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1-917-734-7387

Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com

FAQ

What is the schedule for Sol-Gel Technologies at the Jefferies London Healthcare Conference?

Sol-Gel Technologies will present on November 16, 2021, from 8:00 to 8:35 AM GMT at the Jefferies London Healthcare Conference.

Who is presenting for Sol-Gel Technologies at the Jefferies Conference?

Dr. Alon Seri-Levy, the CEO of Sol-Gel Technologies, will be the speaker at the Jefferies London Healthcare Conference.

What are the main products discussed by Sol-Gel Technologies at the conference?

Sol-Gel Technologies will discuss TWYNEO, FDA-approved for acne, and EPSOLAY, which is pending FDA action for rosacea.

When is the FDA decision expected for EPSOLAY from Sol-Gel Technologies?

The FDA decision for EPSOLAY was expected around April 26, 2021, but has been delayed due to COVID-19 travel restrictions.

How can I listen to Sol-Gel Technologies' presentation at the Jefferies Conference?

You can listen to the presentation live by visiting this link.